Beta

A top financial forum is urging a GST hike, corporate tax cuts, and a radical revamp of retirement savings in its bold 2026 federal budget proposal.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

As it turns six, crypto platform BYDFi expands into traditional finance, bolsters global regulatory compliance, and launches a $1M anniversary event.

As Sri Lanka emerges from its economic crisis, a first-of-its-kind European-regulated fund provides a liquid, secure path to its undervalued assets.

CI Global Asset Management launches innovative funds combining crypto's growth and gold's stability, challenging traditional diversification with a 0% fee offer.